Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies

[1]  H. Soyer,et al.  An Ex Vivo Human Tumor Assay Shows Distinct Patterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes. , 2019, The Journal of investigative dermatology.

[2]  M. Caligiuri,et al.  The mechanism of anti-PD-L1 antibody efficacy against PD-L1 negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector. , 2019, Cancer discovery.

[3]  E. Damonte,et al.  Blockade of dengue virus entry into myeloid cells by endocytic inhibitors in the presence or absence of antibodies , 2018, PLoS neglected tropical diseases.

[4]  K. Kelly,et al.  Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials , 2018, Cancer.

[5]  K. Lewis,et al.  Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial , 2018, Journal of Immunotherapy for Cancer.

[6]  Jazmina L G Cruz,et al.  Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab , 2018, Oncotarget.

[7]  K. Flaherty,et al.  Mechanisms of resistance to immune checkpoint inhibitors , 2018, British Journal of Cancer.

[8]  S. Kent,et al.  Anti-HIV-1 antibody-dependent cellular cytotoxicity: is there more to antibodies than neutralization? , 2017, Current opinion in HIV and AIDS.

[9]  Simon C Watkins,et al.  EGF receptor signaling, phosphorylation, ubiquitylation and endocytosis in tumors in vivo , 2017, eLife.

[10]  F. Rojo,et al.  Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy , 2017, Front. Immunol..

[11]  S. Zolla-Pazner,et al.  Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity , 2017, Scientific Reports.

[12]  A. Craig,et al.  Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers , 2017, Breast Cancer Research.

[13]  A. Scherz,et al.  Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors , 2017, Clinical Cancer Research.

[14]  K. Ikeo,et al.  Lack of interleukin‐6 in the tumor microenvironment augments type‐1 immunity and increases the efficacy of cancer immunotherapy , 2017, Cancer science.

[15]  Yupei Zhao,et al.  Potential Roles of Peripheral Dopamine in Tumor Immunity , 2017, Journal of Cancer.

[16]  Chiou-Feng Lin,et al.  Blockade of dengue virus infection and viral cytotoxicity in neuronal cells in vitro and in vivo by targeting endocytic pathways , 2017, Scientific Reports.

[17]  S. Kron,et al.  Chemical inhibitors of Candida albicans hyphal morphogenesis target endocytosis , 2017, Scientific Reports.

[18]  G. Weinstein,et al.  Barriers to generating PDX models of HPV‐related head and neck cancer , 2017, The Laryngoscope.

[19]  P. Wee,et al.  Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways , 2017, Cancers.

[20]  B. Rath,et al.  Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity , 2017, Expert opinion on biological therapy.

[21]  F. Contreras,et al.  Inhibition of dopamine receptor D3 signaling in dendritic cells increases antigen cross-presentation to CD8+ T-cells favoring anti-tumor immunity , 2017, Journal of Neuroimmunology.

[22]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[23]  R. Scolyer,et al.  Resistance to PD1/PDL1 checkpoint inhibition. , 2017, Cancer treatment reviews.

[24]  Todd M. Allen,et al.  The epigenetic landscape of T cell exhaustion , 2016, Science.

[25]  S. Berger,et al.  Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade , 2016, Science.

[26]  Zhao Zhong （兆忠） Chong （种）.  Targeting PRAS40 for multiple diseases. , 2016, Drug discovery today.

[27]  M. Vetizou,et al.  Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. , 2016, Immunity.

[28]  R. Ferris,et al.  Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients , 2016, Clinical Cancer Research.

[29]  S. Zolla-Pazner,et al.  Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies , 2016, Journal of Virology.

[30]  A. Snyder,et al.  Acquired resistance to immunotherapy and future challenges , 2016, Nature Reviews Cancer.

[31]  Dana Pe'er,et al.  PD-1 Blockade Expands Intratumoral Memory T Cells , 2016, Cancer Immunology Research.

[32]  K. Kelly,et al.  Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer , 2015, Oncoimmunology.

[33]  M. Pistillo,et al.  Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines , 2015, Journal of Translational Medicine.

[34]  C. Antonescu,et al.  Epidermal growth factor–stimulated Akt phosphorylation requires clathrin or ErbB2 but not receptor endocytosis , 2015, Molecular biology of the cell.

[35]  Wei Wang,et al.  NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy , 2015, Front. Immunol..

[36]  James A Daniel,et al.  Phenothiazine‐Derived Antipsychotic Drugs Inhibit Dynamin and Clathrin‐Mediated Endocytosis , 2015, Traffic.

[37]  J. Schlom,et al.  Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells , 2015, Cancer Immunology Research.

[38]  Peter B. Madrid,et al.  Evaluation of Ebola Virus Inhibitors for Drug Repurposing. , 2015, ACS infectious diseases.

[39]  J. Ravetch,et al.  Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect , 2015, Cell.

[40]  B. Nilsson,et al.  Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. , 2015, Cancer cell.

[41]  M. Selig,et al.  Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models , 2015, Nature Medicine.

[42]  Xuefeng Wang,et al.  Upregulated dynamin 1 in an acute seizure model and in epileptic patients , 2015, Synapse.

[43]  Yi-Ling Lin,et al.  Repurposing of prochlorperazine for use against dengue virus infection. , 2015, The Journal of infectious diseases.

[44]  N. Sauvonnet,et al.  Endophilin marks and controls a clathrin-independent endocytic pathway , 2014, Nature.

[45]  N. Iqbal,et al.  Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications , 2014, Molecular biology international.

[46]  S. Akimoto,et al.  Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer. , 2014, Oncology reports.

[47]  C. Creighton,et al.  Erratum to: Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and Histologic characteristics of human cancers , 2014, Journal of Translational Medicine.

[48]  Ira Mellman,et al.  Endocytosis and cancer. , 2013, Cold Spring Harbor perspectives in biology.

[49]  James A Daniel,et al.  Building a Better Dynasore: The Dyngo Compounds Potently Inhibit Dynamin and Endocytosis , 2013, Traffic.

[50]  P. Lang,et al.  Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies , 2013, Front. Immunol..

[51]  F. Meunier,et al.  Targeting membrane trafficking in infection prophylaxis: dynamin inhibitors. , 2013, Trends in cell biology.

[52]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[53]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[54]  J. Wolchok,et al.  Antibody therapy of cancer , 2012, Nature Reviews Cancer.

[55]  R. Levy,et al.  Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. , 2019, The Journal of clinical investigation.

[56]  P. Jänne,et al.  The road to resistance: EGFR mutation and cetuximab , 2012, Nature Medicine.

[57]  M. Schilham,et al.  Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma , 2011, Clinical Cancer Research.

[58]  O. Shupliakov,et al.  Role of the Clathrin Terminal Domain in Regulating Coated Pit Dynamics Revealed by Small Molecule Inhibition , 2011, Cell.

[59]  P. Sondel,et al.  Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity , 2011, Journal of biomedicine & biotechnology.

[60]  G. Thomas,et al.  Tumor-initiating activity and tumor morphology of HNSCC is modulated by interactions between clonal variants within the tumor , 2010, Laboratory Investigation.

[61]  P. Harari,et al.  Understanding resistance to EGFR inhibitors—impact on future treatment strategies , 2010, Nature Reviews Clinical Oncology.

[62]  Eben L Rosenthal,et al.  Optical imaging predicts tumor response to anti-EGFR therapy , 2010, Cancer biology & therapy.

[63]  Byung Min Chung,et al.  Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src@ , 2009, BMC Cell Biology.

[64]  C. Alonso,et al.  Dynamin- and Clathrin-Dependent Endocytosis in African Swine Fever Virus Entry , 2009, Journal of Virology.

[65]  D. Ouwens,et al.  PRAS40: Target or modulator of mTORC1 signalling and insulin action? , 2009, Archives of physiology and biochemistry.

[66]  A. Kraft,et al.  PIM1 Protein Kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells , 2009, Cancer biology & therapy.

[67]  Gerard Manning,et al.  TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. , 2009, Cancer research.

[68]  J. Baselga,et al.  Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity , 2009, Oncogene.

[69]  K. Cortese,et al.  The GTPase-Activating Protein GRAF1 Regulates the CLIC/GEEC Endocytic Pathway , 2008, Current Biology.

[70]  Hayao Nakanishi,et al.  Interleukin‐2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor‐overexpressing gastric cancer xenografts through antibody‐dependent cellular cytotoxicity , 2008, Cancer science.

[71]  Adiel Cohen,et al.  PRAS40 and PRR5-Like Protein Are New mTOR Interactors that Regulate Apoptosis , 2007, PloS one.

[72]  K. Nishio,et al.  Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor , 2007, Cancer science.

[73]  M. Nakamoto,et al.  Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines , 2007, Clinical Cancer Research.

[74]  H. Fujii,et al.  Cetuximab induce antibody‐dependent cellular cytotoxicity against EGFR‐expressing esophageal squamous cell carcinoma , 2007, International journal of cancer.

[75]  J. Eckel,et al.  Insulin-Mediated Phosphorylation of the Proline-Rich Akt Substrate PRAS40 Is Impaired in Insulin Target Tissues of High-Fat Diet–Fed Rats , 2006, Diabetes.

[76]  A. Takaoka,et al.  Comparing antibody and small-molecule therapies for cancer , 2006, Nature Reviews Cancer.

[77]  Robert T. Abraham,et al.  Phosphorylation of Mammalian Target of Rapamycin (mTOR) at Ser-2448 Is Mediated by p70S6 Kinase* , 2005, Journal of Biological Chemistry.

[78]  J. Wang-Rodriguez,et al.  Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. , 2005, American journal of clinical pathology.

[79]  J. Mendelsohn,et al.  Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma , 1993, Cancer Immunology, Immunotherapy.

[80]  M. Sliwkowski,et al.  Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. , 2004, Molecular biology of the cell.

[81]  S. Ménard,et al.  Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 , 2004, Clinical Cancer Research.

[82]  E. Vitetta,et al.  A Comparison of the in Vitro and in Vivo Activities of IgG and F(ab′)2 Fragments of a Mixture of Three Monoclonal Anti-Her-2 Antibodies , 2004, Clinical Cancer Research.

[83]  P. De Camilli,et al.  Dynamin at actin tails , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[84]  J. Hank,et al.  Antibody-directed, effector cell-mediated tumor destruction. , 2001, Hematology/oncology clinics of North America.

[85]  R. Biassoni,et al.  Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. , 2001, Annual review of immunology.

[86]  Y. Yarden,et al.  Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. , 2000, Cancer research.

[87]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[88]  R. Kelly,et al.  SH3-domain-containing proteins function at distinct steps in clathrin-coated vesicle formation , 1999, Nature Cell Biology.

[89]  C. Futter,et al.  Multivesicular endosomes containing internalized EGF-EGF receptor complexes mature and then fuse directly with lysosomes , 1996, The Journal of cell biology.

[90]  N. Goldstein,et al.  Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[91]  S. Schmid,et al.  Induction of mutant dynamin specifically blocks endocytic coated vesicle formation , 1994, The Journal of cell biology.

[92]  H. Sakagami,et al.  Cytotoxicity and differentiation-inducing activity of phenothiazine and benzo[a]phenothiazine derivatives. , 1991, Anticancer research.

[93]  Alexander M. van der Bliek,et al.  Dynamin-like protein encoded by the Drosophila shibire gene associated with vesicular traffic , 1991, Nature.

[94]  W. Wharton,et al.  Effects of phenothiazines on binding and processing of epidermal growth factor in 3T3 cells. , 1986, The American journal of physiology.

[95]  E. Thonnard-Neumann.  Phenothiazines and diabetes in hospitalized women. , 1968, The American journal of psychiatry.